title: Antifibrotic medication using a combination of N-acetyl-L-cystein (NAC) and ACE inhibitors can prevent the recurrence of Dupuytren's disease.
abstract: Dupuytren's disease is a progress fibromatosis of unknown origin first described in 1831. Nonoperative treatment options have been suggested involving radiation therapy, vitamin E, local injection therapy suing calcium channel blockers, interferon, corticosteroids or collagenase. Transforming growth factor-beta1 (TGF-beta1) and its downstream Smad signalling system is well established as a key player during fibrogenesis. A number of in vitro experiments have been assessed the blockade of TGF-beta1 and TGF-beta 2. Clinically, a number of antifibrotic agents are available such as N-acetyl-L-cysteins (NAC) as well as angiotensin-converting enzyme (ACE) inhibitors or AT II antagonists. However, to date none of the well known substances has been tested clinically in fibromatosis such as Dupuytren's disease especially to prevent recurrences after surgical release. Antifibrotic medication using a combination of N-acetyl-L-cystein (NAC) and ACE inhibitor can prevent the recurrence of Dupyutren's disease. Given the fact that recurrence rate in Dupuytren's disease is high and unpredictable after surgical release, an antifibrotic intervention might be worthwhile to consider in the clinical setting. Antifibrotic agents inhibit TGF-beta1, which play a key role in fibromatosis. Thus, antifibrotic medication might reduce the recurrence rate in fibromatosis such as Dupuytren's disease in a clinical significant way.
authors.affiliation: Plastic, Hand and Reconstructive Surgery, Hannover Medical School, Germany. kknobi@yahoo.com
authors.forename: Karsten
authors.initials: K
authors.lastname: Knobloch
authors.forename: Joern
authors.initials: J
authors.lastname: Redeker
authors.forename: Peter M
authors.initials: PM
authors.lastname: Vogt
mesh_terms: D000111:Acetylcysteine / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D004387:Dupuytren Contracture / Q000188:drug therapy*; D005355:Fibrosis / Q000188:drug therapy*; D006801:Humans; D008962:Models, Theoretical; D055502:Secondary Prevention; D053773:Transforming Growth Factor beta1 / Q000037:antagonists & inhibitors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D053773:Transforming Growth Factor beta1; D000111:Acetylcysteine